(Q33758771)

29 July 2017

1 reference

title

Adjuvant medical therapy for prostate cancer (English)

1 reference

29 July 2017

Christopher Sumey

1

1 reference

29 July 2017

Thomas W Flaig

series ordinal

2

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 December 2010

1 reference

Expert Opinion on Pharmacotherapy

29 July 2017

published in

1 reference

29 July 2017

volume

12

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

73-84

1 reference

Cancer survival in five continents: a worldwide population-based study (CONCORD).

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Predictive models in external beam radiotherapy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Adjuvant therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

Management of the side effects of androgen deprivation therapy in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.516252

10.1517/14656566.2010.516252

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference